Evaxion Biotech AS (EVAX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Evaxion Biotech AS stock (EVAX) is currently trading at $3.88. Evaxion Biotech AS PS ratio (Price-to-Sales) is 4.33. Analyst consensus price target for EVAX is $11.25. WallStSmart rates EVAX as Sell.
- EVAX PE ratio analysis and historical PE chart
- EVAX PS ratio (Price-to-Sales) history and trend
- EVAX intrinsic value — DCF, Graham Number, EPV models
- EVAX stock price prediction 2025 2026 2027 2028 2029 2030
- EVAX fair value vs current price
- EVAX insider transactions and insider buying
- Is EVAX undervalued or overvalued?
- Evaxion Biotech AS financial analysis — revenue, earnings, cash flow
- EVAX Piotroski F-Score and Altman Z-Score
- EVAX analyst price target and Smart Rating
Evaxion Biotech AS
📊 No data available
Try selecting a different time range
Smart Analysis
Evaxion Biotech AS (EVAX) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Evaxion Biotech AS (EVAX) Key Strengths (1)
Trading at 1.88x book value, attractively priced
Supporting Valuation Data
Evaxion Biotech AS (EVAX) Areas to Watch (7)
Company is destroying shareholder value
Losing money on operations
Revenue declining -100.00%, a shrinking business
Company is losing money with a negative profit margin
Very low institutional interest at 7.48%
Micro-cap company with very limited liquidity and high volatility
Premium valuation at 4.3x annual revenue
Evaxion Biotech AS (EVAX) Detailed Analysis Report
Overall Assessment
This company scores 19/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 1 register as strengths (avg 8.0/10) while 7 fall into concern territory (avg 1.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book. Valuation metrics including Price/Book (1.88) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (4.33) suggest expensive pricing. Growth concerns include Revenue Growth at -100.00%, which may limit upside. Profitability pressure is visible in Return on Equity at -100.20%, Operating Margin at -122.70%, Profit Margin at -102.40%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -100.20% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -100.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
EVAX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
EVAX's Price-to-Sales ratio of 4.33x trades at a deep discount to its historical average of 141.89x (18th percentile). The current valuation is 99% below its historical high of 843.16x set in Jan 2024, and 25% above its historical low of 3.46x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Evaxion Biotech AS (EVAX) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Evaxion Biotech AS is in a turnaround phase, with management focused on restoring profitability. Revenue reached 8M with 100% decline year-over-year. The company is currently unprofitable, posting a -102.4% profit margin.
Key Findings
Spending 30% of revenue (2M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 100% YoY. Worth determining whether this is cyclical or structural.
The company is unprofitable with a -102.4% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Evaxion Biotech AS.
Bottom Line
Evaxion Biotech AS is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 8:28:17 AM
About Evaxion Biotech AS(EVAX)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Evaxion Biotech A / S, a clinical-stage artificial intelligence and immunology platform company, identifies and develops novel immunotherapies for the treatment of various cancers, bacterial diseases, and viral infections. The company is headquartered in Hoersholm, Denmark.